Table 2.
Median adherence percentage with inter-quartile range at each study visit, by adherence measure
| n | Week 16 | n | Week 48 | |
|---|---|---|---|---|
| Self-report (%): median (IQR) | 140 | 100 (100–100) | 169 | 100 (100–100) |
| Pill count (%): median (IQR) | 160 | 100 (92–100) | 178 | 100 (95–107) |
| Average pharmacy refill (%): median (IQR)a | 158 | 104 (101–105) | 178 | 103 (95–105) |
| Gaps pharmacy refill (%): median(IQR)a | 158 | 100 (100–100) | 178 | 100 (95–100) |
| EAMD adherence (%): median (IQR)a | 160 | 93 (74–98) | 180 | 86 (59–94) |
| EFV concentration (mg/L): median(IQR) | 136 | 2.3 (1.6–4.4) | 156 | 2.1 (1.5–3.4) |
| Viral suppression: n (%) | 160 | 146 (91.2) | 180 | 153 (85.0) |
Self-report and EFV concentrations are measured on the date of the visit. Tablet counts cover the 30 days (week 16) or 60 days (week 48) before the visit. Pharmacy refill and EAMD adherence are cumulative data from baseline to latest time in care
aCumulative per protocol measures